Researchers at the Jefferson Institute of Molecular Medicine at Thomas Jefferson University (TJU) have received a $384,000 grant from the U.S. National Institutes of Health (NIH) to investigate how nephrogenic systemic fibrosis (NSF) develops.
NSF is a serious and sometimes fatal skin disorder linked to gadolinium-based contrast agents used in MRI and MR angiography studies.
TJU researchers, led by Dr. Sergio Jimenez, co-director of the Jefferson Institute, will investigate the role of macrophages and their cell-surface receptors, known as Toll-like receptors, in the hope of developing new treatments for the disease.
